Literature DB >> 17318545

Fully automatic differential diagnosis system for dementia with Lewy bodies and Alzheimer's disease using FDG-PET and 3D-SSP.

Atsushi K Kono1, Kazunari Ishii, Keitaro Sofue, Naokazu Miyamoto, Setsu Sakamoto, Etsuro Mori.   

Abstract

PURPOSE: To evaluate a fully automatic computer-assisted diagnostic system for mild dementia with Lewy bodies (DLB), permitting distinction from mild Alzheimer's disease (AD).
METHODS: Using 18F-fluorodeoxyglucose and positron emission tomography (FDG-PET), glucose metabolic images were obtained from mild DLB and mild AD patients. Two groups consisting of 16 mild DLB patients and 21 mild AD patients were recruited for diagnostic evaluation between mild DLB and mild AD. The mean age+/-SD of the mild DLB group and the mild AD group was 74.3+/-4.9 and 71.7+/-2.1 years, respectively, and the mean scores of the MMSE for the mild DLB and the mild AD group were 21.7+/-1.9 and 23.1+/-2.1, respectively. A receiver operating characteristic (ROC) analysis was performed to compare the diagnostic performance, in terms of discrimination between DLB and AD, of conventional axial FDG-PET images inspected visually by experts and beginners with that of our fully automatic diagnosis system using the statistical brain mapping method and Z scores obtained with the DLB template.
RESULTS: The diagnostic performance of the automatic system was comparable to that of visual inspection by experts. The area under the ROC curve for the automatic diagnosis system was 0.77. The mean area under the ROC curve for visual inspection by experts and beginners was 0.76 and 0.65, respectively.
CONCLUSION: The fully automatic differential diagnosis system for distinction between mild DLB and AD showed a similar diagnostic accuracy to visual inspection by experts. It would be a useful diagnostic tool to distinguish mild DLB from mild AD in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17318545     DOI: 10.1007/s00259-007-0380-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  26 in total

1.  Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI.

Authors:  M Gerlach; K Stadler; F Aichner; G Ransmayr
Journal:  Neurology       Date:  2002-11-12       Impact factor: 9.910

2.  Clinically and neuropathologically distinct form of dementia in the elderly.

Authors:  R H Perry; D Irving; G Blessed; E K Perry; A F Fairbairn
Journal:  Lancet       Date:  1989-01-21       Impact factor: 79.321

3.  Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD.

Authors:  K Lobotesis; J D Fenwick; A Phipps; A Ryman; A Swann; C Ballard; I G McKeith; J T O'Brien
Journal:  Neurology       Date:  2001-03-13       Impact factor: 9.910

4.  Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation.

Authors:  S Minoshima; N L Foster; A A Sima; K A Frey; R L Albin; D E Kuhl
Journal:  Ann Neurol       Date:  2001-09       Impact factor: 10.422

5.  [DaT-SCAN SPECT in the differential diagnosis of dementia with Lewy bodies and Alzheimer's disease].

Authors:  J Vaamonde-Gamo; J M Flores-Barragán; R Ibáñez; M Gudín; A Hernández
Journal:  Rev Neurol       Date:  2005 Sep 1-15       Impact factor: 0.870

6.  The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity.

Authors:  L Hansen; D Salmon; D Galasko; E Masliah; R Katzman; R DeTeresa; L Thal; M M Pay; R Hofstetter; M Klauber
Journal:  Neurology       Date:  1990-01       Impact factor: 9.910

7.  Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease.

Authors:  R L Albin; S Minoshima; C J D'Amato; K A Frey; D A Kuhl; A A Sima
Journal:  Neurology       Date:  1996-08       Impact factor: 9.910

8.  Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains.

Authors:  K Ishii; F Willoch; S Minoshima; A Drzezga; E P Ficaro; D J Cross; D E Kuhl; M Schwaiger
Journal:  J Nucl Med       Date:  2001-04       Impact factor: 10.057

Review 9.  Role of dopamine transporter imaging in routine clinical practice.

Authors:  Vicky Marshall; Donald Grosset
Journal:  Mov Disord       Date:  2003-12       Impact factor: 10.338

10.  Comparison of FDG-PET and IMP-SPECT in patients with dementia with Lewy bodies.

Authors:  Kazunari Ishii; Kayo Hosaka; Tetsuya Mori; Etsuro Mori
Journal:  Ann Nucl Med       Date:  2004-07       Impact factor: 2.668

View more
  21 in total

1.  Measurement of gray and white matter atrophy in dementia with Lewy bodies using diffeomorphic anatomic registration through exponentiated lie algebra: A comparison with conventional voxel-based morphometry.

Authors:  R Takahashi; K Ishii; N Miyamoto; T Yoshikawa; K Shimada; S Ohkawa; T Kakigi; K Yokoyama
Journal:  AJNR Am J Neuroradiol       Date:  2010-07-15       Impact factor: 3.825

Review 2.  Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia.

Authors:  Peter J Nestor; Daniele Altomare; Cristina Festari; Alexander Drzezga; Jasmine Rivolta; Zuzana Walker; Femke Bouwman; Stefania Orini; Ian Law; Federica Agosta; Javier Arbizu; Marina Boccardi; Flavio Nobili; Giovanni Battista Frisoni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-07       Impact factor: 9.236

3.  Brain (18)F-FDG, (18)F-Florbetaben PET/CT, (123)I-FP-CIT SPECT and Cardiac (123)I-MIBG Imaging for Diagnosis of a "Cerebral Type" of Lewy Body Disease.

Authors:  Axel Van Der Gucht; Laurent Cleret de Langavant; Ophélie Bélissant; Corentin Rabu; Anne-Ségolène Cottereau; Eva Evangelista; Julia Chalaye; Sophie Bonnot-Lours; Gilles Fénelon; Emmanuel Itti
Journal:  Nucl Med Mol Imaging       Date:  2016-01-29

Review 4.  Current Role for Biomarkers in Clinical Diagnosis of Alzheimer Disease and Frontotemporal Dementia.

Authors:  Nasim Sheikh-Bahaei; Seyed Ahmad Sajjadi; Aimee L Pierce
Journal:  Curr Treat Options Neurol       Date:  2017-11-14       Impact factor: 3.598

Review 5.  Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders.

Authors:  Flavio Nobili; Cristina Festari; Daniele Altomare; Federica Agosta; Stefania Orini; Koen Van Laere; Javier Arbizu; Femke Bouwman; Alexander Drzezga; Peter Nestor; Zuzana Walker; Marina Boccardi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-02       Impact factor: 9.236

Review 6.  Imaging biomarkers associated with cognitive decline: a review.

Authors:  Jonathan McConathy; Yvette I Sheline
Journal:  Biol Psychiatry       Date:  2014-09-16       Impact factor: 13.382

7.  Computer-assisted system for diagnosis of Alzheimer disease using data base- independent estimation and fluorodeoxyglucose- positron-emission tomography and 3D-stereotactic surface projection.

Authors:  T Uemura; K Ishii; N Miyamoto; T Yoshikawa
Journal:  AJNR Am J Neuroradiol       Date:  2011-02-03       Impact factor: 3.825

8.  Diagnostic performance of an automated analysis software for the diagnosis of Alzheimer's dementia with 18F FDG PET.

Authors:  Sasan Partovi; Roger Yuh; Sara Pirozzi; Ziang Lu; Spencer Couturier; Ulrich Grosse; Mark D Schluchter; Aaron Nelson; Robert Jones; James K O'Donnell; Peter Faulhaber
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-01-15

9.  Computer-assisted diagnostic system for neurodegenerative dementia using brain SPECT and 3D-SSP.

Authors:  Kazunari Ishii; Tomonori Kanda; Takafumi Uemura; Naokazu Miyamoto; Toshiki Yoshikawa; Kenichi Shimada; Shingo Ohkawa; Satoshi Minoshima
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-16       Impact factor: 9.236

10.  Urinary incontinence and its functional anatomy in frontotemporal lobar degenerations.

Authors:  Robert Perneczky; Janine Diehl-Schmid; Hans Förstl; Alexander Drzezga; Florian May; Alexander Kurz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-30       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.